- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03242317
A Prospective Study to Evaluate the Raindrop Near Vision Inlay With Mitomycin C
A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopes Treated With Mitomycin C During Surgery and Extended Steroid After Surgery
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Registrering (Forventet)
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
New York
-
Amherst, New York, Forente stater, 14228
- Rekruttering
- Fichte Endl & Elmer Eyecare
-
Ta kontakt med:
- Micheal J Endl, MD
- Telefonnummer: 716-564-2020
- E-post: mpderme@aol.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Patients require a near reading add from +1.5 to +2.5 D in the non-dominant eye.
Patients have a photopic pupil size of at least 3.0 mm in the non-dominant eye. Patients have a corneal thickness greater than or equal to 500 microns in the non-dominant eye.
Patients have corrected distance and near visual acuity of 20/25 or better in each eye.
Patients have distance corrected near visual acuity of 20/40 or worse in each eye.
Patients are willing and able to sign and understand a written Informed Consent Form prior to any study-specific procedures.
Patients are willing and able to return for scheduled follow-up examinations for 24 months after the corneal inlay surgery.
Exclusion Criteria:
Patients with prior ocular surgery. Patients with clinically significant dry eye (i.e., significant diffuse punctate staining with fluorescein and a tear breakup time less than 8 s) in either eye.
Patients with a planned corneal residual bed thickness that is less than 300 microns (corneal thickness - (intended ablation depth + intended flap thickness)).
Patients with macular pathology based on dilated fundus exam and/or optical coherence tomography (OCT) image.
Patients who would be co-managed by an ophthalmologist or optometrist who is not approved as a ReVision Optics investigator.
Patients with ocular pathology or disease (including pupil pathology such as fixated pupils) that might confound the outcome or increase the risk of adverse event.
Patients taking systemic or topical medications that might confound the outcome or increase the risk of adverse event. Patients taking isotretinoin or amiodarone hydrochloride and any other medication that affects the tear film or accommodation, including but not limited to, mydriatic, cycloplegic and mitotic agents, tricyclic, phenothiazines, benzodiazepines, and first generation antihistamines.
Patients with known sensitivity to any planned study medications. Patients with residual, recurrent, active or uncontrolled eyelid disease. Patients with significant corneal asymmetry or irregular topography. Patients with clinically significant anterior segment pathology. Patients with any corneal abnormality, including but not limited to, slit lamp findings for corneal staining Grade 3 or higher, recurrent corneal erosion or severe basement membrane disease, and pterygium extending onto the cornea.
Patients with ophthalmoscopic/topographic signs of keratoconus or those who are keratoconus suspect.
Patients with history of Herpes zoster or Herpes simplex keratitis. Patients with any progressive retinal disease or subjects with a history or evidence of retinal vascular occlusion and/or hypercoagulability, because of the risks associated with high pressures during suction application.
Patients with known history of steroid-responsive intraocular pressure increases, glaucoma, preoperative IOP > 21 mm Hg, or are otherwise suspected of having glaucoma.
Patients with amblyopia or strabismus or those who are at risk for developing strabismus postoperatively as determined by corneal light reflex and cover-uncover testing.
Patients with diabetic retinopathy, collagen, vascular, diagnosed autoimmune disease (e.g., lupus, rheumatoid arthritis, fibromylagia), immunodeficiency (e.g., HIV), connective tissue disease, or clinically significant atopic syndrome such as allergies or asthma.
Patients on chronic systemic corticosteroid or other immunosuppressive therapy that may affect wound healing.
Patients with any type of active cancer (ophthalmic or non-ophthalmic). Patients with uncontrolled infections of any kind. Patients who are pregnant, lactating, of child-bearing potential and not practicing a medically approved method of birth control, or planning to become pregnant during the course of the trial, and patients with other conditions associated with fluctuation of hormones that could lead to refractive changes.
Patients who actively participate in contact sports (i.e., boxing, martial arts) where impacts to the face and eye are a normal occurrence.
Patients participating in any other ophthalmic or non-ophthalmic drug/device clinical trials during the time of this clinical investigation.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Mitomycin C + Raindrop Near Vision Inlay
The surgical procedure includes a low dose, short duration MMC treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the Raindrop Near Vision Inlay in Presbyopes.
|
The surgical procedure includes a low dose, short duration MMC treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the corneal inlay.
This treatment is at a concentration of 0.2 mg/mL (0.02%) applied for 10 to 30 seconds on the stromal bed as well as the stromal side of the corneal flap or pocket.
The surgical procedure includes the unilateral implantation of the Raindrop Near Vision Inlay in the non-dominant eye for the improvement of uncorrected near vision.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Ukorrigert synsskarphet
Tidsramme: 24 måneder
|
Etter innleggsprosedyren vil pasientene oppnå funksjonell nærsynsstyrke i innleggsøyet og funksjonell avstandsskarphet kikkert.
|
24 måneder
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Forekomst av hornhinnereaksjon
Tidsramme: 24 måneder
|
Pasienter som behandles med lav dose, kortvarig MMC intraoperativt, deretter vil et utvidet lavdose-steroidregime ha minimale nivåer av hornhinnereaksjon.
|
24 måneder
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Michael J Endl, MD, Fichte, Endl & Elmer Eyecare
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- FEE17-001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Presbyopi
-
Bausch & Lomb IncorporatedFullførtMyopi og Hyperopi og presbyopiForente stater
-
Technolas Perfect Vision GmbHUkjent
-
University of WaterlooAlcon ResearchRekruttering
-
Jennifer FogtAlcon ResearchRekrutteringPresbyopiForente stater
-
Optall VisionRekruttering
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityHar ikke rekruttert ennå
-
Novartis PharmaceuticalsAvsluttetPresbyopiCanada, Forente stater, Australia, Japan
-
Visioneering Technologies, IncFullført
-
Coopervision, Inc.Fullført
Kliniske studier på Mitomycin C
-
Guy's and St Thomas' NHS Foundation TrustUkjentPrimær åpen vinkelglaukomStorbritannia
-
University of California, San DiegoFullførtÅpen vinkelglaukom
-
National Cancer Institute (NCI)FullførtSolid neoplasmaForente stater
-
Medical Enterprises Ltd.AvsluttetKreft i urinblæren | Blærekreft | Ondartet svulst i urinblæren | Blæreneoplasma | Blærekreft | Karsinom in situ i blæren | Blæresvulster | Blærekreft | Neoplasmer, blære | Papillarkarsinom i blæren (diagnose) | BCG - Ikke-responsiv blærekreftForente stater
-
Prakash PandalaiRekruttering
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Van Andel Research InstituteTilbaketrukketBukspyttkjertelkreftForente stater
-
Indiana UniversityOptonolAvsluttet
-
Jørgen Bjerggaard JensenAktiv, ikke rekrutterende
-
Croatian Cooperative Group for Clinical Research...Roche Pharma AGUkjentBrystkreft | MetastaseKroatia
-
University of Rome Tor VergataUniversity Of Perugia; University of L'AquilaFullførtBlærekreft TNM Staging Primærtumor (T) Ta | Blærekreft TNM Staging Primærtumor (T) T1 | Blærekreft overgangscellegradItalia